Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Open-Label Dose Optimization Period	STARTED	d-Amphetamine Transdermal Patch	110
Open-Label Dose Optimization Period	STARTED	Placebo Patch	0
Open-Label Dose Optimization Period	COMPLETED	d-Amphetamine Transdermal Patch	106
Open-Label Dose Optimization Period	COMPLETED	Placebo Patch	0
Open-Label Dose Optimization Period	NOT COMPLETED	d-Amphetamine Transdermal Patch	4
Open-Label Dose Optimization Period	NOT COMPLETED	Placebo Patch	0
Double-blind Cross-Over Treatment Period	STARTED	d-Amphetamine Transdermal Patch	53
Double-blind Cross-Over Treatment Period	STARTED	Placebo Patch	53
Double-blind Cross-Over Treatment Period	COMPLETED	d-Amphetamine Transdermal Patch	46
Double-blind Cross-Over Treatment Period	COMPLETED	Placebo Patch	46
Double-blind Cross-Over Treatment Period	NOT COMPLETED	d-Amphetamine Transdermal Patch	7
Double-blind Cross-Over Treatment Period	NOT COMPLETED	Placebo Patch	7

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01711021/flow